Boston Scientific (NYSE:BSX) Sets New 52-Week Low - Here's What Happened

Key Points

• Boston Scientific shares fell to a new 52-week low of $41.94, below its 50-day and 200-day moving averages, before trading around $42.28.
• Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $70.19, although some firms recently lowered targets or downgraded the stock.
• The company exceeded quarterly expectations with $0.86 in adjusted EPS and $5.44 billion in revenue, while insiders purchased roughly $9.4 million of shares in the latest quarter.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) reached a new 52-week low during mid-day trading on Friday. The stock traded as low as $41.94 and last traded at $42.2780, with a volume of 1531121 shares. The stock had previously closed at $43.23.

Analyst Ratings Changes

A number of research analysts have recently commented on BSX shares. Argus restated a "hold" rating on shares of Boston Scientific in a research report on Friday, July 31st. Oppenheimer lowered their price objective on Boston Scientific from $85.00 to $65.00 and set an "outperform" rating on the stock in a research report on Monday, September 21st. Evercore set a $65.00 price objective on Boston Scientific in a research note on Monday, July 6th. Weiss Ratings cut Boston Scientific from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Tuesday, July 7th. Finally, TD Cowen reaffirmed a "buy" rating on shares of Boston Scientific in a report on Thursday, September 17th. Twenty-three equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $70.19.

Boston Scientific Price Performance

The firm has a fifty day moving average of $46.99 and a two-hundred day moving average of $51.70. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $62.20 billion, a PE ratio of 17.37, a PEG ratio of 1.05 and a beta of 0.58.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts' consensus estimates of $0.83 by $0.03. The business had revenue of $5.44 billion for the quarter, compared to analysts' expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The business's quarterly revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific Corporation will post 3.26 EPS for the current fiscal year.

Insider Buying and Selling at Boston Scientific

In other news, CEO Michael Mahoney purchased 186,240 shares of the business's stock in a transaction on Monday, August 3rd. The shares were acquired at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward Ludwig acquired 5,000 shares of the stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the purchase, the director owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 194,522 shares of company stock valued at $9,385,210 in the last quarter. Company insiders own 0.34% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

A number of large investors have recently made changes to their positions in the business. Renaissance Group LLC purchased a new position in shares of Boston Scientific during the 4th quarter valued at about $28,064,000. Perigon Wealth Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at $883,000. Y Intercept Hong Kong Ltd lifted its position in shares of Boston Scientific by 148.8% in the second quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider's stock worth $47,816,000 after buying an additional 670,060 shares in the last quarter. Wealthfront Advisers LLC purchased a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $3,253,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab raised its stake in Boston Scientific by 9.9% during the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider's stock valued at $13,659,000 after purchasing an additional 28,961 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.